Replies to post #27346 on Biotech Values

[io_io]

re: STJ & DSCO


How about DSCO ? It's drifting again, near a 52-week low. Priced like a company in mid-phase III trials, whereas in fact only CMC issues remain. Big pipeline too in areas with sparse competition. Defintiely getting near my target for a purchase.